Publications by authors named "D Teta"
Introduction: The gut barrier, comprising gut microbiota, plays a pivotal role in chronic kidney disease (CKD) progression and nutritional status. This study aimed to explore gut barrier alterations in hemodialyzed (HD) patients, non-HD (NHD) CKD patients, and healthy volunteers.
Methods: Our cross-sectional study enrolled 22 HD patients, 11 NHD patients, and 11 healthy volunteers.
The beneficial effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown recently in numerous randomized controlled trials (RCT) and systematic reviews. According to KDIGO guidelines, SGLT2i currently represent a first choice for diabetic patients with chronic kidney disease (CKD). In addition, a recent meta-analysis of 13 large led by the 'SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium' (SMART-C) provided solid evidence of SGLT2i beneficial effects in CKD or in patients with heart failure, with and without diabetes.
View Article and Find Full Text PDFArticle Synopsis
- Primary IgA nephropathy is a common kidney disease that varies widely in how it affects people, and while it was once thought to be mostly harmless, nearly 40% of cases can lead to severe kidney failure within 20-30 years.
- Recent research has helped clarify how the disease works, allowing for better predictions and more aggressive treatments for those with worsening conditions.
- The article discusses both traditional and new treatment options, like sparsentan and targeted-release budenoside, as well as promising new therapies focusing on complement and B cell inhibitors, signaling a potential shift in how we manage this condition.